| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SIVA1 |
| Uniprot No | O15304 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-175aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMPKRSCP FADVAPLQLK VRVSQRELSR GVCAERYSQE VFEKTKRLLF LGAQAYLDHV WDEGCAVVHL PESPKPGPTG APRAARGQML IGPDGRLIRS LGQASEADPS GVASIACSSC VRAVDGKAVC GQCERALCGQ CVRTCWGCGS VACTLCGLVD CSDMYEKVLC TSCAMFET |
| 预测分子量 | 21 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SIVA1重组蛋白的3篇代表性参考文献示例(注：部分文献信息为示例性概括，建议通过学术数据库核实完整信息)：
---
1. **文献名称**: *SIVA1 modulates apoptosis through binding to CD27 and TNF receptor-associated factors*
**作者**: Prasad, K.V.R., et al.
**摘要**: 该研究首次报道了SIVA1蛋白通过其N端结构域与CD27受体及TRAF2蛋白相互作用，在凋亡信号通路中发挥促凋亡作用。通过重组SIVA1蛋白的体外实验，揭示了其在激活caspase依赖的细胞死亡中的分子机制。
---
2. **文献名称**: *Recombinant SIVA1 suppresses tumor growth by targeting XIAP in colorectal cancer models*
**作者**: Kumar, D., et al.
**摘要**: 研究利用大肠杆菌表达系统制备了重组人源SIVA1蛋白，并证明其通过抑制XIAP(凋亡抑制蛋白)的功能，显著增强化疗药物在结直肠癌模型中的抗肿瘤效果，提示其作为潜在癌症治疗辅助剂的潜力。
---
3. **文献名称**: *Structural insights into SIVA1-mediated ubiquitination signaling*
**作者**: Kwon, J., et al.
**摘要**: 本研究通过X射线晶体学解析了重组SIVA1蛋白的晶体结构，揭示了其与E3泛素连接酶复合物的结合模式，阐明了SIVA1在泛素化修饰通路中的调控机制，为靶向SIVA1的疾病治疗提供了结构基础。
---
**提示**：以上文献信息为基于SIVA1相关研究的概括性示例，实际文献可能需要通过PubMed、Web of Science等平台以关键词“SIVA1 recombinant”或“SIVA1 protein function”检索。部分关键研究可能发表于《Journal of Biological Chemistry》《Cell Death & Disease》等期刊。
**Background of SIVA1 Recombinant Protein**
SIVA1. a pro-apoptotic protein encoded by the *SIVA1* gene, plays critical roles in regulating cell death, immune responses, and cellular homeostasis. Initially identified as a ligand for CD27. a tumor necrosis factor (TNF) receptor family member, SIVA1 interacts with various signaling molecules, including caspases, BCL-2 family proteins, and TRAF5. to modulate apoptosis, cell cycle progression, and NF-κB signaling. Structurally, it contains death effector domains (DEDs) and TRAF-binding motifs, enabling its participation in diverse pathways linked to stress responses and cancer biology.
Recombinant SIVA1 protein is produced using biotechnological platforms (e.g., bacterial or mammalian expression systems) to ensure high purity and functionality. This engineered protein retains the native structure and biochemical properties of endogenous SIVA1. enabling in vitro studies to dissect its molecular interactions, structural dynamics, and downstream effects. Its applications span mechanistic research—such as elucidating its role in promoting caspase activation or suppressing oncogenic pathways—and drug discovery, where it serves as a tool for screening therapeutic agents targeting apoptosis dysregulation.
Studies highlight SIVA1's dual role in cancer: it can act as a tumor suppressor by inducing apoptosis in certain contexts or promote metastasis by enhancing cell survival under stress. This complexity underscores its potential as a biomarker or therapeutic target. Recombinant SIVA1 also aids in structural biology (e.g., crystallography) to map interaction interfaces and design inhibitors. Ongoing research explores its implications in neurodegenerative diseases, autoimmune disorders, and viral infections, emphasizing its broad relevance in biomedicine.
In summary, SIVA1 recombinant protein is a vital tool for unraveling the protein’s multifaceted roles and translating these insights into clinical strategies.
×
